Municipal Employees Retirement System of Michigan lifted its stake in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 68.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,210 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,300 shares during the period. Municipal Employees Retirement System of Michigan’s holdings in Eagle Pharmaceuticals were worth $191,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in EGRX. Janus Henderson Group PLC purchased a new stake in shares of Eagle Pharmaceuticals during the second quarter worth about $144,384,000. Thrivent Financial For Lutherans increased its stake in shares of Eagle Pharmaceuticals by 17,917.8% during the second quarter. Thrivent Financial For Lutherans now owns 828,820 shares of the specialty pharmaceutical company’s stock worth $65,386,000 after purchasing an additional 824,220 shares in the last quarter. Old Mutual Global Investors UK Ltd. increased its stake in shares of Eagle Pharmaceuticals by 271.6% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 386,132 shares of the specialty pharmaceutical company’s stock worth $23,028,000 after purchasing an additional 282,225 shares in the last quarter. Lazard Asset Management LLC increased its stake in shares of Eagle Pharmaceuticals by 1,045.7% during the second quarter. Lazard Asset Management LLC now owns 278,108 shares of the specialty pharmaceutical company’s stock worth $21,939,000 after purchasing an additional 253,833 shares in the last quarter. Finally, Prudential Financial Inc. increased its stake in shares of Eagle Pharmaceuticals by 808.7% during the third quarter. Prudential Financial Inc. now owns 222,072 shares of the specialty pharmaceutical company’s stock worth $13,244,000 after purchasing an additional 197,634 shares in the last quarter.

A number of analysts have recently commented on EGRX shares. Piper Jaffray Companies reissued a “buy” rating and set a $75.00 target price on shares of Eagle Pharmaceuticals in a research note on Friday, October 27th. ValuEngine upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. BidaskClub upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, December 2nd. Royal Bank of Canada restated an “outperform” rating and set a $75.00 price target (down from $81.00) on shares of Eagle Pharmaceuticals in a research report on Thursday, November 9th. Finally, Mizuho restated a “sell” rating and set a $37.00 price target on shares of Eagle Pharmaceuticals in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $62.33.

Eagle Pharmaceuticals, Inc. (NASDAQ EGRX) opened at $55.68 on Friday. The firm has a market cap of $858.29, a PE ratio of 9.07 and a beta of 1.24. Eagle Pharmaceuticals, Inc. has a 52-week low of $45.05 and a 52-week high of $97.15. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.15 and a current ratio of 5.30.

COPYRIGHT VIOLATION WARNING: “Municipal Employees Retirement System of Michigan Grows Stake in Eagle Pharmaceuticals, Inc. (EGRX)” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/12/15/municipal-employees-retirement-system-of-michigan-grows-stake-in-eagle-pharmaceuticals-inc-egrx.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.